HER2DX ERBB2 mRNA score in first-line advanced HER2-positive breast cancer treated with chemotherapy, trastuzumab, and pertuzumab
Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Aleix Prat(Hospital Clínic de Barcelona), Valeria Sirenko(Breast Cancer Research Foundation), Esther Carcelero(Hospital Clínic de Barcelona), Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Angela Aguirre, Manuel Alva(Hospital Universitario 12 De Octubre), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), Cristina González-Deza(Hospital Universitario 12 De Octubre), Luís Manso(Research Institute Hospital 12 de Octubre), Tomás Pascual(Breast Cancer Research Foundation), Jesús Soberino(Hospital Quirónsalud Barcelona), Patricia Galván(Vall d'Hebron Institute of Oncology), Charles M. Perou(University of North Carolina at Chapel Hill), Paula Blasco(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), María Cobos-Fernández(Hospital Universitario 12 De Octubre), Olga Martínez‐Sáez(Breast Cancer Research Foundation), Isabel García-Fructuoso(Breast Cancer Research Foundation), Esther Sanfeliu(Hospital Clínic de Barcelona), Julia Maués, Laia Paré(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Eva Ciruelos(Hospital Universitario 12 De Octubre), Patricia Villagrasa, Wesley Buckingham(Hospital Costa del Sol), Mercedes Marín‐Aguilera(Oryzon Genomics (Spain)), Ainhoa Madariaga(Hospital Universitario 12 De Octubre), Elia Seguí, Laura Lema(Hospital Universitario 12 De Octubre), María Rey(Center for Cancer and Blood Disorders), Astrid Mayhua(Hospital Universitario 12 De Octubre), Oleguer Castillo(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Denys Romero-Romero(Hospital Universitario 12 De Octubre), Pablo Tolosa(Research Institute Hospital 12 de Octubre)
Cited by 6
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma
|Clinical Cancer Research|2004|2.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k